HK1053839A1 - Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same. - Google Patents

Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same.

Info

Publication number
HK1053839A1
HK1053839A1 HK03106201A HK03106201A HK1053839A1 HK 1053839 A1 HK1053839 A1 HK 1053839A1 HK 03106201 A HK03106201 A HK 03106201A HK 03106201 A HK03106201 A HK 03106201A HK 1053839 A1 HK1053839 A1 HK 1053839A1
Authority
HK
Hong Kong
Prior art keywords
azaindoles
phosphodiesterase
inhibitors
novel
producing
Prior art date
Application number
HK03106201A
Other languages
English (en)
Inventor
Norbert Hofgen
Ute Egerland
Thomas Kronbach
Degenhard Marx
Stefan Szelenyi
Hildegard Kuss
Emmanuel Polymeropoulos
Original Assignee
Elbion Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10053275A external-priority patent/DE10053275A1/de
Application filed by Elbion Ag filed Critical Elbion Ag
Publication of HK1053839A1 publication Critical patent/HK1053839A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
HK03106201A 2000-10-27 2003-08-29 Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same. HK1053839A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10053275A DE10053275A1 (de) 2000-10-27 2000-10-27 Neue 7-Azaindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
US24434200P 2000-10-30 2000-10-30
PCT/EP2001/012376 WO2002034747A1 (fr) 2000-10-27 2001-10-25 Nouveaux 7-azaindoles, leur utilisation en tant qu'inhibiteurs de la phosphodiesterase 4 et leur procede de production

Publications (1)

Publication Number Publication Date
HK1053839A1 true HK1053839A1 (en) 2003-11-07

Family

ID=26007507

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03106201A HK1053839A1 (en) 2000-10-27 2003-08-29 Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same.

Country Status (28)

Country Link
US (3) US7169787B2 (fr)
EP (1) EP1330455B1 (fr)
JP (1) JP4233322B2 (fr)
KR (2) KR100837099B1 (fr)
CN (1) CN1247576C (fr)
AR (1) AR034269A1 (fr)
AT (1) ATE301121T1 (fr)
AU (2) AU2175302A (fr)
BG (1) BG66169B1 (fr)
BR (1) BR0114903A (fr)
CA (1) CA2428468C (fr)
CZ (1) CZ20031146A3 (fr)
DE (1) DE50106993D1 (fr)
DK (1) DK1330455T3 (fr)
EE (1) EE05271B1 (fr)
ES (1) ES2246349T3 (fr)
HK (1) HK1053839A1 (fr)
HR (1) HRP20030427B1 (fr)
HU (1) HUP0303034A3 (fr)
IL (2) IL155386A0 (fr)
MX (1) MXPA03003624A (fr)
NO (1) NO324947B1 (fr)
NZ (1) NZ525369A (fr)
PL (1) PL213999B1 (fr)
PT (1) PT1330455E (fr)
SK (1) SK287774B6 (fr)
TW (1) TWI262920B (fr)
WO (1) WO2002034747A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014761A1 (en) * 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
MXPA05004780A (es) * 2002-11-06 2005-10-05 Celgene Corp Metodos y composiciones que usan farmacos inhibidores selectivos de citocina para el tratamiento y el manejo de canceres y otros padecimientos.
DE10318610A1 (de) 2003-04-24 2004-11-11 Elbion Ag 7-Azaindole und deren Verwendung als Therapeutika
US20050054691A1 (en) * 2003-08-29 2005-03-10 St. Jude Children's Research Hospital Carboxylesterase inhibitors
CN102060806A (zh) * 2003-09-11 2011-05-18 iTherX药品公司 细胞因子抑制剂
US7585859B2 (en) * 2004-05-06 2009-09-08 Plexxikon, Inc. PDE4B inhibitors and uses therefor
MY144903A (en) 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
EP1786813A2 (fr) * 2004-09-03 2007-05-23 Plexxikon, Inc. Inhibiteurs de la phosphodiesterase 4b (pde4b)
CA2628570A1 (fr) 2005-11-09 2007-05-18 Combinatorx, Incorporated Procedes, compositions et kits pour le traitement de pathologies
GB0525143D0 (en) 2005-12-09 2006-01-18 Novartis Ag Organic compounds
CA2651732C (fr) 2006-05-18 2014-10-14 Mannkind Corporation Inhibiteurs de kinases intracellulaires
US20100056791A1 (en) * 2006-09-01 2010-03-04 Yasushi Kohno Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same
US8012992B2 (en) * 2008-06-30 2011-09-06 Allergan, Inc. Aza-indoles and related compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
ES2478289T3 (es) * 2008-09-22 2014-07-21 Isis Innovation Ltd Bisfosfonatos de 5-azaindol
US8816085B2 (en) * 2009-08-26 2014-08-26 Takeda Gmbh Methylpyrrolopyridinecarboxamides
WO2012072727A1 (fr) 2010-12-03 2012-06-07 Biotie Therapies Gmbh Modification cristalline du n(3,5-dichloropyridin-4-yl)-[1-(4-fluorobenzyl)-7-azaindol-3-yl)]glyoxylamide servant d'inhibiteur de la pde4
WO2012080329A1 (fr) * 2010-12-17 2012-06-21 Biotie Therapies Gmbh Formulations d'amide de l'acide n-(3,5-dichloropyridin-4-yl)-[1-(4-fluorobenzyl)-7-azaindol-3-yl)]glyoxylique
CN102584842A (zh) * 2011-01-17 2012-07-18 北京大学 取代吲哚并内酰胺衍生物的制备及作为抗疟疾剂的用途
CN113679717A (zh) 2012-08-22 2021-11-23 康奈尔大学 用于抑制肌成束蛋白的方法
CA3195815A1 (en) * 2014-02-20 2015-08-27 Cornell University Compounds and methods for inhibiting fascin
CN113164487A (zh) * 2018-10-12 2021-07-23 内布拉斯加大学董事委员会 磷酸二酯酶抑制剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1141949A (en) 1966-02-23 1969-02-05 Sterling Drug Inc 7-azaindole derivatives
WO1991009598A1 (fr) 1990-01-05 1991-07-11 Pfizer Inc. Derives de l'azaoxindole
US5023265A (en) 1990-06-01 1991-06-11 Schering Corporation Substituted 1-H-pyrrolopyridine-3-carboxamides
US5811432A (en) 1990-11-09 1998-09-22 Pfizer Inc Azaoxindole derivatives
PL307265A1 (en) 1992-07-28 1995-05-15 Rhone Poulenc Rorer Ltd Compounds containing a phenyl group bonded with aryl or heteroaryl group through their bonding aliphatic group or that containing heteroatom
CA2140440A1 (fr) 1992-08-06 1994-02-17 Ellen M. Dobrusin 2-thioindoles (selenoindoles) et disulfides appparentes (selenides) qui inhibent les proteine-tyrosine-kinases et qui ont des proprietes antitumorales
JP3119758B2 (ja) * 1993-02-24 2000-12-25 日清製粉株式会社 ７−アザインドール誘導体及びこれを有効成分とする抗潰瘍薬
AU699085B2 (en) 1994-04-21 1998-11-19 Schering Aktiengesellschaft PDE IV inhibitors for treating Multiple Sclerosis
GB9420521D0 (en) 1994-10-12 1994-11-30 Smithkline Beecham Plc Novel compounds
GB9507297D0 (en) 1995-04-07 1995-05-31 Rh Ne Poulenc Rorer Limited New composition of matter
JPH09169665A (ja) 1995-12-21 1997-06-30 Kenichi Miyamoto 骨粗鬆症治療剤
JP3601898B2 (ja) 1996-02-14 2004-12-15 俊隆 鍋島 薬物依存形成抑制剤
AUPO282996A0 (en) 1996-10-07 1996-10-31 Fujisawa Pharmaceutical Co., Ltd. Novel compounds
AU3868500A (en) * 1999-03-10 2000-09-28 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone

Also Published As

Publication number Publication date
HUP0303034A2 (hu) 2003-12-29
KR20080016758A (ko) 2008-02-21
HRP20030427B1 (en) 2006-04-30
NO20031722L (no) 2003-04-14
DK1330455T3 (da) 2005-12-05
US20060258700A1 (en) 2006-11-16
MXPA03003624A (es) 2004-12-02
BG107725A (bg) 2004-08-31
PL362837A1 (en) 2004-11-02
HRP20030427A2 (en) 2003-08-31
KR100837099B1 (ko) 2008-06-13
CN1247576C (zh) 2006-03-29
HUP0303034A3 (en) 2012-12-28
IL155386A (en) 2008-06-05
PL213999B1 (pl) 2013-06-28
ES2246349T3 (es) 2006-02-16
AR034269A1 (es) 2004-02-18
US20080207680A1 (en) 2008-08-28
SK5092003A3 (en) 2004-08-03
US20040106641A1 (en) 2004-06-03
KR20030065499A (ko) 2003-08-06
US7419987B2 (en) 2008-09-02
DE50106993D1 (de) 2005-09-08
AU2002221753B2 (en) 2006-12-14
IL155386A0 (en) 2003-11-23
NO324947B1 (no) 2008-01-07
NO20031722D0 (no) 2003-04-14
PT1330455E (pt) 2005-10-31
BG66169B1 (bg) 2011-10-31
NZ525369A (en) 2004-09-24
ATE301121T1 (de) 2005-08-15
JP4233322B2 (ja) 2009-03-04
US7683074B2 (en) 2010-03-23
SK287774B6 (sk) 2011-09-05
KR100880586B1 (ko) 2009-01-30
WO2002034747A1 (fr) 2002-05-02
CA2428468C (fr) 2011-06-14
US7169787B2 (en) 2007-01-30
BR0114903A (pt) 2003-10-14
EP1330455A1 (fr) 2003-07-30
AU2175302A (en) 2002-05-06
EE200300166A (et) 2003-08-15
CZ20031146A3 (cs) 2003-10-15
EP1330455B1 (fr) 2005-08-03
EE05271B1 (et) 2010-02-15
CA2428468A1 (fr) 2002-05-02
CN1484644A (zh) 2004-03-24
TWI262920B (en) 2006-10-01
JP2004512337A (ja) 2004-04-22

Similar Documents

Publication Publication Date Title
TWI315741B (en) A-isomaltosyltransferase, process for producing the same and use thereof
HK1053839A1 (en) Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same.
AU2002222293A1 (en) Pyrazolo(3,4-c)pyridines as gsk-3 inhibitors
AU2002221753A1 (en) Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same
PL351148A1 (en) 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof
PL392790A1 (pl) Związki pirazolo [3, 4-b] pirydynowe i ich zastosowanie jako inhibitorów fosfodiesterazy
IL160440A0 (en) Novel dihydropteridinones, method for producing the same and the use thereof as medicaments
HK1049834A1 (zh) 用作磷酸二酯酶抑制劑的5-(2-取代的-5-雜環基磺酰基吡啶-3-基)-二氫吡唑並[4，3-d]嘧啶-7-酮類化合物
HK1054034A1 (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors.
PL371059A1 (en) 5-phenylpyrimidines, agents comprising the same, method for production and use thereof
AU2001294228A1 (en) Benzimidazole compounds, process for producing the same and use thereof
ZA200207489B (en) Apomorphine derivatives and methods for their use.
AU2001272329A1 (en) Ultrahydrophobic surfaces, methods for the production thereof and their use
PL351616A1 (en) Polyolefin compositions, method for the production and use thereof
ZA200208346B (en) Polyamide nucleic acid derivatives, agents and methods for producing the same.
IL156162A0 (en) Coniosetin and derivatives thereof, method for producing the same and use thereof.
ZA200303236B (en) Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same.
ZA200002546B (en) Sorbate-preserved compositions, method for the manufacture thereof and their use.
AU2002227966A1 (en) Coniosetin and derivatives thereof, method for producing the same and use thereof
AU2001286188A1 (en) Tricyclic heterocyclic compound, process for producing the same, and use thereof
EP1273657A4 (fr) Nouvelle proteine, son procede de production et d'utilisation
SI1330455T1 (sl) Novi 7-azaindoli, njihova uporaba kot inhibitorji fosfodiesteraze 4 in postopek za njihovo pripravo
IL157793A0 (en) Caloporoside derivatives, methods for the production thereof and their use
MXPA03004632A (es) Klainetina y sus derivados, metodo para su produccion y su uso.
IL137364A (en) Process for the preparation of 6,6-dimethylhept-1-en-4-yn-3-ol

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20131025